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As part of an increasing worldwide use of designer drugs, recent use of compounds 
containing cathinones and synthetic cannabinoids is especially prevalent. Here, we 
reviewed current literature on the prevalence, epidemiology, bio-behavioral effects, 
and detection of these compounds. Gender differences and clinical effects will also be 
examined. Chronic use of synthetic cathinone compounds can have major effects on the 
central nervous system and can induce acute psychosis, hypomania, paranoid ideation, 
and delusions, similar to the effects of other better-known amphetamine-type stimulants. 
Synthetic cannabinoid products have effects that are somewhat similar to those of natu-
ral cannabis but more potent and long-lasting than THC. Some of these compounds are 
potent and dangerous, having been linked to psychosis, mania, and suicidal ideation. 
Novel compounds are developed rapidly and new screening techniques are needed to 
detect them as well as a rigorous regulation and legislation reinforcement to prevent 
their distribution and use. Given the rapid increase in the use of synthetic cathinones 
and cannabinoid designer drugs, their potential for dependence and abuse, and harmful 
medical and psychiatric effects, there is a need for research and education in the areas 
of prevention and treatment.
Keywords: synthetic drugs, cathinones, cannabis, amphetamine, new psychoactive drugs
iNTRODUCTiON
Over the past decade, there has been a worldwide increase in the opportunity for use and consump-
tion of Novel Psychoactive Substances (NPS) – which produce “legal highs” (1–8). Usually mimicking 
the psychoactive effects of illicit drugs of abuse, these “designer” drugs vary widely in composition, 
and are mainly sold online and from street retailers. Some of the drugs are advertised as being legal 
and are often labeled as “not for human consumption” or “licensed by the Ministry of Health,” to 
bypass—legislation enforcement. Based on their pharmacological mechanisms and psychoactive 
properties, designer drugs fall into four major categories: (i) amphetamine-like stimulants, which 
include cathinones derivatives and piperazine derivatives that are sold as substitutes for “ecstasy,” 
(ii) synthetic cannabinoids, (iii) hallucinogenic/dissociative agents, and (iv) opioid-like compounds 
(9). While new compounds are appearing relentlessly on the drug market, information regarding their 
potential toxicity is scarce and the number of emergencies related to their use is increasing (10, 11). 
Given the public health threat that is growing in complexity, a multidisciplinary coordinated effort 
is required to elucidate the acute and chronic effects of synthetic drugs of abuse (12). According to 
2Weinstein et al. Synthetic Cathinones and Cannabinoids
Frontiers in Psychiatry | www.frontiersin.org August 2017 | Volume 8 | Article 156
the World Drug Report 2016 (13), the majority of the substances 
reported for the first time between 2012 and 2014 were synthetic 
cannabinoids, followed by synthetic cathinones that have been 
steadily increasing since their first appearance (2010). Synthetic 
cathinones and synthetic cannabinoids have been studied more 
extensively than other classes of NPS (e.g., new hallucinogens and 
opioid-like compounds) over the past 10 years. These two classes 
of substances are the most popular, both induce central and 
peripheral serious effects and activate the brain reward system 
thus showing to possess abuse potential (14, 15). Since they pose 
a major health hazard potential, this review will focus on these 
two classes of NPS.
Synthetic cathinones are psychostimulants related to the 
naturally occurring parent compound cathinone (16, 17), 
a monoamine alkaloid found in the khat plant (Catha edulis), 
a flowering plant native to the Horn of Africa and the Arabian 
Peninsula that is being chewed in these areas for thousands of 
years. Cathinone is a psychoactive substance known to cause 
excitement, loss of appetite, and euphoria. As members of the 
phenethylamine class of drugs, they are structurally and phar-
macologically similar to amphetamine and 3,4-methylenediox-
ymethamphetamine (MDMA). The most commonly used drugs 
in this class have been 4-methylmethcathinone (mephedrone), 
3,4-methylenedioxy-N-methylcathinone (methylone), and 
4-methylenedioxypyrovalerone (MDPV), although MDPV and 
mephedrone are no longer prevalent (16, 17). Reports of abuse of 
cathinone derivatives date back to the 1990s, when mephedrone 
was the first designer drug of this class (18). Mephedrone is the 
most widely abused synthetic cathinone in Europe, and MDPV 
and methylone are the most frequently abused synthetic cathi-
nones in the United States (7). These drugs have been commonly 
referred to as “bath salts,” “plant food,” or “fertilizer,” because 
they were at times disguised and commonly included in products 
that were labeled and sold as such (7, 9). New analogs, legal to 
possess, at least until they are formally banned, are frequently 
introduced, and it has been estimated that nearly 250 new analogs 
are produced each year (19). These drugs are consumed by oral 
ingestion, inhalation, and snorting. Notably, the recent trend to 
supplement use of more conventional psychostimulants, such as 
amphetamine and cocaine, with mephedrone, may lead to seri-
ous psychotic, neurological, cardiovascular, and sexual health 
consequences (4).
Synthetic cannabinoid receptor agonists, which often mimic 
the effects of marijuana, are added to herbs, such as Damiana 
leaves, and sold under different brand names, such as “Spice” or 
Mr. Nice Guy in Europe since 2006 (20, 21). These products are 
also called “K2,” “herbal incense,” “Cloud 9,” “Mojo,” and with 
many other names (22). Advertised as “exotic incense blends 
which release a rich aroma,” Spice, and Spice-like preparations 
in Europe have been found to contain different substances with 
various chemical structures, including those (i) based on over 450 
compounds originally produced for medical research by John W. 
Huffman (e.g., JWH-018), (ii) HU-210 developed by Raphael 
Mechoulam at the Hebrew University, and (iii) the cyclohexyl-
phenol (“CP”) cannabinoids developed at Pfizer Pharmaceuticals 
(23). AM-2201, an indole derivative, which differs from JWH-
018 by a fluorine atom in the pentyl chain, is commonly found in 
Korea and has nanomolar affinity for cannabinoid receptors (24). 
After the appearance on the drug market of over 100 compounds 
that activate cannabinoid receptors, new compounds with differ-
ent chemical structures that directly or indirectly stimulate the 
cannabinoid CB1 receptors are expected. The perceived harmful-
ness of synthetic cannabinoids among secondary school students 
(twelfth grade) increased between 2012 (the first year of meas-
urement) and 2014, which may have contributed to the decline 
in use (9). This review is divided into the following categories: 
epidemiology of use, pharmacology, neuropsychiatric findings, 
other medical conditions, and regulation.
ePiDeMiOLOGY
Synthetic Cathinones
Masticating khat leaves has been a social habit among Saudi 
Arabian and East African cultures, for several centuries. Cathinone 
is the main psychoactive ingredient that was detected in the leaves 
of the C. edulis. In the Middle East and in East Africa khat use 
is still common, more among men than women, although the 
gap is narrowing (25). Yet, although both sexes typically report 
to use khat to upkeep of tradition, men’s use is more frequently 
associated to recreational purposes, while women often report to 
use it to treat headache or lose weight (26).
Recent surveys have considered the problem of synthetic 
cathinones use in the United States. In an online survey of 113 
participants, who reported use of synthetic cathinones, respond-
ents were males, with age range of 18–24 years, and Caucasian 
holding college education (27). Their use in the past year was low 
(≤10  days), but recurrent. The intranasal route of administra-
tion was most frequently reported, and its effects were similar 
to those of cocaine and amphetamines. Synthetic cathinones 
increased sexual desire and sexual risk-taking behavior. More 
than half of the responders met DSM-V diagnostic criteria for 
a substance-related disorder. Self-reported prevalence of the use 
of synthetic cathinones was less than that of marijuana, cocaine, 
Salvia divinorum, synthetic cannabinoids, methamphetamine, 
and MDMA. In another survey, reaching over 2,300 students 
at a large university in the Southeastern United States, 1.07% 
of respondents endorsed ever using synthetic cathinones, and 
those who did were more often men than women, Hispanics, and 
Native American rather than Caucasian students, and athletes 
more than non-athletes (27).
Studies of synthetic cathinones use in Europe have also been 
informative. In Hungary, there has been a shift among street drug 
users from the use of heroin to mephedrone injection, poten-
tially increasing the risk of severe psychiatric symptom profile 
and increased possibility of dependence (28). Among 1,000 
individuals who completed a survey in schools and universities 
in Scotland (49.8% males and 50.2% females), 20.3% reported 
previous use mephedrone, with 23.4% reporting single use and 
4.4% daily use (29). In a survey of 249 NPS users interviewed in 
open public places, clubs, and discotheques in Slovenia, 67.9% 
of the respondents endorsed having tried either synthetic cathi-
nones or amphetamines (30). Of those who reported using syn-
thetic cathinones or amphetamines, most reported having used 
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3-methylmethcathinone first, 43.0% had first used methylone, 
and 37.3% had first used mephedrone. Users have associated the 
new drugs with high risks and favored traditional drugs. A report 
on the occurrence and trends of new synthetic drugs in Sweden 
included participants who were 13–63 (median 20) years of age 
(31). The report described a widespread use of NPS in adolescents 
and young male adults (79%), in incidents of drug intoxications 
reported by emergency departments and intensive care units. 
Of the 189 blood and urine samples that were examined in the 
laboratory, 156 (83%) samples were found positive for NPS. More 
than 50 new synthetic drugs were detected. These included syn-
thetic cannabinoid receptor agonists (“Spice”), piperazines, sub-
stituted phenethylamines, synthetic cathinones, hallucinogenic 
tryptamines, piperidines, opioid-related substances, ketamine 
and related substances, and γ-aminobutyric acid analogs. About 
half of the cases involved multiple drug intoxications, making it 
hard to link the clinical presentations with one specific substance.
Synthetic Cannabinoids
Synthetic cannabinoid users are usually men in their twenties, 
who use also other drugs. In a study of adult marijuana and 
tobacco users, the 42 respondents were male young adults, high 
school graduates, who also smoked tobacco and cannabis (86% 
smoked cannabis on five or more days per week) (32). A very 
high proportion (91%) were familiar with synthetic cannabinoid 
products, half (50%) smoked them previously, and a minority 
(24%) used them over the last month. Common reasons for use 
included expecting a strong “high” while avoiding detection by 
urine toxicology. The main side effects were difficulties in think-
ing, anxiety, dry mouth, and headache. Students also used syn-
thetic cannabinoids out of curiosity and for feeling “high” (33). 
Eleven adolescents experienced euphoria and negative effects on 
memory, and nine reported negative mood changes (34).
Several informative surveys of synthetic cannabinoids use 
have involved college students. In a study of 852 college students 
in the United States, 69 (8%) reported using the drugs at least 
once, and more common use in males and in the first or second 
year of college (35). A survey of students from a local health clinic 
and a US University found 9, 5, and 3% lifetime, past-year, and 
past 30-day use of synthetic cannabinoids, respectively (36). In 
Rhode Island, 1,080 young (18–25 years old) participants were 
surveyed between January 2012 and July 2013, and 9% reported 
use of synthetic cannabinoids in the last month. Synthetic can-
nabinoid users were predominantly males who did not attend 
school, smoked cigarettes, were binge alcohol drinkers, who used 
marijuana daily, as well as other recreational drugs (37). A survey 
of over 3,100 college students in North Carolina and Virginia 
showed that lifetime prevalence of synthetic cannabinoids was 
7.6% at college entry and 6.6% first use during college (38). 
During the fourth year of college, lifetime synthetic cannabinoids 
use was reported by 17.0%. The “Monitoring the Future study,” 
a nationally representative sample of high school seniors between 
2011 and 2013 included almost 12,000 participants of mean age 
18 (39). In this sample, 10% reported any recent use and 3% 
reported frequent use (over six times) of synthetic cannabinoids. 
Females were less likely to use synthetic cannabinoids, and going 
out 4–7 evenings per week increased likelihood of drug use. 
Several factors were identified as increasing the risk for synthetic 
cannabinoid use, mainly high frequency of lifetime marijuana 
use, lifetime use of alcohol, cigarettes, and other illicit drugs. 
Among 396 patients entering residential treatment for Substance 
Use Disorder in the United States, 150 reported using synthetic 
cannabinoids in their lifetime. Motives for drug use were curi-
osity (91%), “feeling good” or “getting high” (89%), relaxation 
(71%), and “getting high” while avoiding detection (71%) (40). 
According to the 2009–2013 US National Survey of Drug Use and 
Health, the gender gap in the self-reported use of synthetic can-
nabinoids is smaller compared to other categories of NPS among 
non-institutionalized individuals aged 12–34 years old (41).
In an anonymous online survey among almost 15,000 
participants in the UK, 2,513 (17%) reported use of synthetic 
cannabinoids. Among them, 41% reported use over the last 
12 months (42). Almost all synthetic cannabinoids users (99%) 
used natural cannabis at least once. Synthetic cannabinoids had 
a shorter effect and faster time to peak effect than natural can-
nabis. Most users (93%) preferred natural cannabis to synthetic 
cannabinoids. Natural cannabis had greater pleasurable effects 
when “high” and allowed better function after use. Synthetic can-
nabinoids had negative effects such as hangover, and paranoia. 
In an anonymous follow-up online survey of drug use with over 
22,000 respondents, use of synthetic cannabinoids was estimated 
as 30 times as more risky than natural cannabis (43).
In Australia, a sample of 316 synthetic cannabinoid users (77% 
male, mean age 27 years) reported mean synthetic cannabinoid 
use of 6 months, 35% reported weekly use and 7% reported daily 
use (44). Reasons for first use included: curiosity (50%), legality 
(39%), availability (23%), recreational effects (20%), therapeutic 
effects (9%), avoidance of detection by standard drug screening 
tests (8%), and aid for the reduction or cessation of cannabis use. 
In a further study of over 1,100 students (mean age 14.9 years) 
from secondary schools in Australia, 2.4% had ever used synthetic 
cannabis and 0.4% had used synthetic stimulants (45). Users also 
had an episode of binge drinking in the past 6  months, used 
tobacco and had higher levels of psychological distress and lower 
perceived self-efficacy to resist peer pressure than non-users, but 
did not differ from users of other illicit drugs.
Comparative epidemiology
In a survey covering the years 2009 to 2012 in the United States, 
synthetic cathinone and synthetic cannabis exposures totaled 
7,467 and 11,561, respectively (46), with increases in the use of 
both from 2009 to 2011. Synthetic cathinone use increased from 
none reported in 2009, to 298 in 2010, and 6,062 in 2011. By 
comparison, there were 14 reported synthetic cannabis exposures 
in 2009, 2,821 in 2010, and 6,255 in 2011. The number of those 
who were first-time exposed to synthetic cathinones was lower 
in 2012 (1,007) than in 2011 (2,027), while the number of first-
time exposures to synthetic cannabis was higher in 2012 (2,389) 
than in 2011 (1,888) possibly reflecting a shift from synthetic 
cathinone use toward the use of synthetic cannabinoids. Most 
exposures occurred in the Midwest and Southeastern US (64.8% 
of synthetic cathinone and 58% of synthetic cannabis expo-
sures). Males comprised 69% (n = 5,153) of synthetic cathinone 
users and 74% (n =  8,505) of synthetic cannabis users. Use of 
TabLe 1 | Studies investigating the behavioral effects of synthetic cathinones.
animals Synthetic cathinone 
tested
Main findings Reference
Male ICR mice α-PBP, α-PPP, α-PVP Motor stimulation (50–52)
MDPV Decreased motor 
coordination
MEPH Ataxia
Methylone
3-FMC, 4-FMC, 
4-MePPP
Male Sprague-
Dawley rats
α-PVP Significantly lower 
ICSS threshold 
(53–55)
MDPV
MEPH
Methcathinone
Methylone
R-MEPH, 4-MEC
Male rats (Wistar, 
Sprague-Dawley)
α-PVT Sustain IVSA 
behavior
(56–63)
BMAPN
Buphedrone
MACHP
Methylone
MPDV
4-MEC, 4-MePPP
Male mice (CD-1, 
ICR, C57BL/6J or 
Swiss Webster)
α-PBP, α-PVP, α-PVT Induce CPP (58–62,  
64, 65)BMAPN
Buphedrone
MACHP, MDPV
MEPH, MAOP
Methylone
PIPP
Male and female 
(MDPV) Sprague-
Dawley rats
MDPV Induce CPP (55, 66–68)
R-MEPH
4-MEC
Male Sprague-
Dawley rats
α-PBP, α-PVP, α-PVT Substitute for the 
discriminative 
stimulus effects 
of METH in a DD 
paradigm
(61, 65,  
69, 70)Methcathinone
Pentedrone
Pentylone
3-FMC, 4-MePPP, 
4-MEC
α-PBP, α-pyrrolidinopropiobutiophenone; α-PVP, alpha-pyrrolidinovalerophenone 
α-PVT, alpha-pyrrolidinopentiothiophenone; buphedrone, [2-(methylamino)-1-
phenylbutan-1-one, α-methylamino-butyrophenone]; BMAPN, 2-(methylamino)-
1-(naphthalen-2-yl) propan-1-one; CPP, conditioned place preference; DD, 
drug discrimination; ICSS, intracranial self-stimulation; IVSA, intravenous self-
administration; MACHP, [1] 2-cyclohexyl-2-(methylamino)-1-phenylethanone; MAOP, [2] 
2-(methylamino)-1-phenyloctan-1-one; MEPH, mephedrone; METH, metamphetamine; 
MDPV, methylenedioxyphyrovalerone; PIPP, f α-piperidinopropiophenone; R-MEPH, 
R-mephedrone; 3-FMC, 3-fluoromethcathinone; 4-FMC, 4-fluoromethcathinone; 
4-MEC, 4-methylethcathinone; 4-MePPP, 4-methyl-alpha-pyrrolidinopropiophenone.
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synthetic cathinones was highest in individuals 20–29  years of 
age (n = 2,943), while use of synthetic cannabinoids was high-
est for younger respondents, i.e., individuals 13–19  years of 
age (n =  5,349). A recent study involving 1,740 young adults 
recruited in US nightlife scenes (18–40 years old, mean age 26.4) 
showed that use of mephedrone and synthetic cannabinoids 
adults in US nightlife scenes is lower than in EU nightlife scenes 
(47). Specifically, 8.2% used synthetic cannabinoids, 1.1% used 
mephedrone. Gay and bisexual men reported more frequent use 
of mephedrone and more frequent use of synthetic cannabinoid 
use in individuals with Latin origin. In conclusion, synthetic can-
nabis emerged first with overall more reported exposures than 
synthetic cathinone. In 2012, synthetic cathinone abuse declined 
while synthetic cannabis abuse increased. Young men intention-
ally abusing synthetic cannabinoids via inhalation make up the 
majority of users.
DRUG PHaRMaCOLOGY, CeNTRaL 
eFFeCTS, aND CLiNiCaL FeaTUReS
Synthetic Cathinones
Synthetic cathinones represent a broad class of pharmacologi-
cally active compounds that induce numerous effects with dif-
ferent mechanisms of action. As such, each case of synthetic 
cathinone intoxication should be evaluated separately, at least 
until preclinical research will provide structure–activity rela-
tionships for each compound. Similar to the action of other 
psychostimulants, synthetic cathinones have an effect on plasma 
membrane transporters of the monoamine neurotransmitters, 
dopamine, norepinephrine, and serotonin (48). Mephedrone 
and methylone, but not MDPV, act as non-selective transporter 
agonists, thereby promoting release of all of these neurotransmit-
ters. Conversely, MDPV acts as a potent blocker at catechola-
mine transporters with little effect at the serotonin transporter 
(48). Mephedrone or methylone administered to rats increase 
extracellular concentrations of dopamine and serotonin in the 
brain, similar to the effects of MDMA (48). Synthetic cathinones 
elicit locomotor stimulation in rodents similar to other psych-
stimulants. The enhanced dopamine transmission by synthetic 
cathinones presents a high potential for addiction that may result 
in adverse effects (49). See Table 1 for behavioral and pharmaco-
logical effects of synthetic cathinones in rodents.
Acute and Chronic Side Effects
Acute administration of low doses of synthetic cathinones pro-
duces euphoria and increases alertness, but high doses or chronic 
use can result in serious adverse effects, such as hallucinations, 
delirium, hyperthermia, and tachycardia (70). Repeated use of 
synthetic cathinones is associated with paranoia and hallucina-
tions and some patients developed “excited delirium,” a syndrome 
with symptoms of extreme agitation and violent behavior (70). 
The symptoms included dehydration, muscle damage and 
renal failure that may result in multi-organ failure and death. A 
40-year-old male, who had no previous psychiatric history devel-
oped “excited delirium” after ingesting “bath salts” with psychosis 
and violence (71). Forty-three postmortem cases with detected 
synthetic cathinones had the following associated causes of 
death: driving under the influence of drugs (17 cases), domestic 
violence (2 cases), suicide (4 cases), overdose (12 cases), accidents 
(6 cases), drug-facilitated assault (1 case), and homicide (1 case) 
(72). The highest measured MDPV and methylone concentra-
tion was detected in a case of suicide by hanging and in a driver, 
respectively. A single case of death following methylone ingestion 
was reported in France (73).
Cardiovascular effects (tachycardia, hypertension) and hal-
lucinations are the most recurrent medical complications of 
synthetic cathinone use. The most frequently reported unwanted 
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clinical effects among cases reported to Texas poison centers 
during 2010–2011 were tachycardia (45.9%), agitation (39.2%), 
hypertension (21.0%), hallucinations (17.7%), and confusion 
(13.0%) (74). A study of “bath-salt” exposure conducted in two 
poison centers in the United States found primarily neurologi-
cal and cardiovascular effects. Drugs effects included agitation, 
combative behavior, tachycardia, hallucinations, paranoia, con-
fusion, chest pain, myoclonus, hypertension, mydriasis, eleva-
tions in creatine phosphokinase, hypokalemia, blurred vision, 
and death (8). Signs of severe toxicity, such as hyperthermia, 
metabolic acidosis and prolonged rhabdomyolysis, indicative of 
high serotonergic activity, were also reported (75). A single case 
described cardiovascular manifestations, including tachycardia, 
hypertension, myocardial infarction, arrhythmias, and cardiac 
arrest (76).
Seizures and Withdrawal
Synthetic cathinone exposure has also resulted in many cases of 
seizures in the pediatric population. The American Association 
of Poison Control Centers database was used to examine 
synthetic cathinone exposures in children and youth below 
20 years of age between 2010 and 2013 (77). There were 1,328 
cases of pediatric synthetic cathinone exposures, of which 73 
cases presented seizures complications: 37 (50.7%) involved a 
single seizure, 29 (39.7%) involved multiple seizures, and seven 
(9.6%) developed epilepsy. Fever and acidosis were associated 
with single seizures, multiple seizures, and status epilepsy. There 
were no correlations between seizure activity and electrolyte 
abnormalities, hallucinations and/or delusions, tachycardia, or 
hypertension. The most commonly co-ingested substances were 
tetrahydrocannabinol, alcohol, and opioids. Finally, in Italy, a 
baby born to a woman who was a chronic consumer of 4-methy-
lethcathinone showed symptoms of neonatal withdrawal syn-
drome (78). The newborn presented with increased jitteriness 
and irritability, high-pitched crying, limbs hypertonia and brisk 
tendon reflexes (78).
Regrettably, there is little information regarding the phar-
macokinetics of synthetic cathinones in preclinical or clinical 
studies. Studies conducted so far have demonstrated that, upon 
systemic administration, synthetic cathinones are metabolized in 
several phase I compounds, some of which have been found to 
be substrates at monoamine transporters when assessed in vitro 
or to exert neurochemical actions in vivo (79, 80). The resulting 
metabolites can also partially undergo phase II metabolism (81). 
The presence of active metabolites could account, at least in part, 
for the diversified effects of these drugs.
Synthetic Cannabinoids
Unlike Δ9-tetrahydrocannabinol (THC), synthetic cannabinoids 
are extremely potent, highly efficacious, full agonists of the 
cannabinoid receptors (82, 83), including CB1 receptors in the 
brain (84–89). There is substantial variability in the molecular 
constituents of different compounds, between assortment of 
the same product, and even within a package (20). In addition 
to synthetic cannabinoids, Spice drugs may contain preserva-
tives, additives, fatty acids, amides, esters, the benzodiazepine 
phenazepam and O-desmethyltramadol, an active metabolite 
of the opioid medication tramadol (90–92). Studies in rodents 
have indicated that most synthetic cannabinoids produce effects 
and toxicity that, overall, are similar to those of THC and include 
hypothermia, analgesia, hypo-locomotion, and akinesia (93). 
Yet, most effects are more potent and long-lasting than THC. 
See Table  2 for motor and reward-related behavioral effects of 
synthetic cannabinoids in rodents.
Psychosis
Cannabis use has potential for inducing psychosis [for recent 
reviews, see Ref. (107, 108)], and it would be reasonable to expect 
synthetic cannabinoids to have the same effect. Because of their 
high potency and the fact that synthetic cannabinoids act as full 
cannabinoid receptor agonists, even short or occasional use of 
these synthetic compounds can produce unwanted effects, such as 
insomnia, memory impairment, headaches, dizziness, and delu-
sions. Moreover, unlike natural cannabis, synthetic cannabinoids 
contain no cannabidiol that may be protective against psychosis. 
Cannabidiol antagonizes the psychotomimetic and other psycho-
tropic effects of THC although the mechanisms underlying its 
therapeutic effect are still not clear (109). Compared with natural 
cannabis, synthetic cannabinoids may cause more frequent and 
more severe unwanted negative effects, and may have high-risk 
for psychosis especially in young users (110). Case reports have 
documented psychosis (111, 112), mania (113), and suicidal idea-
tions (114) in synthetic cannabinoid users.
Brain Imaging Studies
Although brain imaging studies have pointed to abnormalities 
in cerebral perfusion, deficits in brain volume and white-matter 
pathways (115), brain imaging has scarcely been applied to 
understand the neural correlates of synthetic cannabis use. A 
comparison of 20 male patients who had used synthetic can-
nabinoids with 20 healthy male controls indicated that drug users 
had smaller gray-matter volume in the thalamus and the cerebel-
lum (116). A single case study of a 23-year-old patient reported 
severe withdrawal syndrome upon voluntary abstinence from 
“Spice Gold.” Craving, affective symptoms and a range of somatic 
complaints were reported, but these were resolved after several 
days of monitored abstinence (117). In this patient, dopamine D2 
and D3 receptor availability was 20% lower in the striatum and in 
extra-striatal regions with respect to healthy control participants, 
but returned to control values with detoxification. Brain imag-
ing studies suggest that synthetic cannabinoid use can produce 
remarkable changes in the brain, but they are still preliminary, 
and the extent and duration of the neural sequelae of synthetic 
cannabinoid use remains to be determined.
Effects on Driving
Reports concerning driving under the influence of synthetic can-
nabinoids also reflect their impact on the nervous system. One 
report from the United States indicated that drivers under the 
influence of synthetic cannabinoids had slow and slurred speech, 
and poor coordination (118). A survey in Germany found behav-
ioral deficits that were moderate except for worsening of paranoia 
in one case (119). The symptoms were similar to the effects of 
cannabinoid agonists but could also be a result of alcohol or other 
TabLe 2 | Studies investigating the behavioral effects of synthetic cannabinoids.
animals Synthetic cannabinoid tested Main findings Reference
Male mice (C57BL/6J, Swiss Webster) “Buzz” (5.4% JWH-018) Induces a dose-related tetrad effects similar  
to marijuana/THC
(94, 95)
JWH-018
JWH-073
Male Swiss Webster/ICR mice AB-FUBINACA Decrease locomotor activity (96–99)
AM-2201 Induce catalepsy
APINACA/AKB-48
JWH-018, JWH-073, JWH-200, JWH-203 
JWH-250
PB-22 (QUPIC)
UR-144, XLR-11, 5F-PB-22
Male ICR mice JWH-018 Significantly impairs sensorimotor functions (14, 99)
Induced convulsions, myoclonia and hyperreflexia  
(at high doses)
Male Sprague-Dawley rats/C57BL/6 mice JWH-018 Sustains IVSA behavior (100)
Male mice (ICR) JWH-073, JWH-081, JWH-210 Induce CPP (101)
Male Sprague-Dawley rats JWH-175 Induces CPP (102)
Male ND4 Swiss–Webster/ICR mice AB-CHMINACA Fully substitute for THC in a DD paradigm (98, 103)
AB-PINACA
ADBICA
ADB-PINACA
FUBIMINA
JWH-018, JWH-122, JWH-210
RCS-4, THJ-2201
Male and female (JWH-018) Sprague-
Dawley rats 
AB-FUBINACA Fully substitute for THC in a DD paradigm (96, 97, 104)
AM-2201
APINACA/AKB-48
JWH-018, JWH-073, JWH-200, JWH-203, 
JWH-250
PB-22/QUPIC
UR-144, XLR-11, 5F-PB-22
Male adolescent rhesus monkeys JWH-018 Shows discriminative stimulus effects; dose-dependently 
increases drug-lever responding and decreased response 
rate
(105)
Female and male adult rhesus monkeys AM-2201 Substitute for the discriminative stimulus effects of Δ9-THC (106)
JWH
JWH
AB-CHMINACA, N-[1-amino-3-methyl-oxobutan-2-yl]-1-[cyclohexylmethyl]-1H-indazole-3-carboxamide; AB-FUBINACA, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-
1H-indazole-3-carboxamide; AB-PINACA, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide; ADBICA, N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-
pentyl-1H-indole-3-carboxamide; ADB-PINACA, N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-pentyl-1H-indazole-3-carboxamide; AM-2201, [1-(5-fluoropentyl)-1H-indol-3-yl]-
1-naphthalen-methanone; APINACA/AKB-48, N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide; CPP, conditioned place preference; DD, drug discrimination; FUBIMINA, 
(1-(5-fluoropentyl)-1H-benzo[d]imadazol-2-yl)(naphthalen-1-yl)methanone; ICSS, intracranial self-stimulation; IVSA, intravenous self-administration; JWH-018,1-pentyl-3-(1-naphthoyl)
indole; JWH-073, naphthalen-1-yl-(1-butylindol-3-yl)methanone; JWH-081, 4-methoxynaphthalen-1-yl-(1-pentylindol-3-yl)methanone; JWH-175, (1-pentylindol-3-yl) naphthalen-
1-ylmethane; JWH-200, [1-[2-(morpholinyl)ethyl]-1H-indol-3-yl]-1-naphthalenyl-methanone; JWH-203, (2-(2-chlorophenyl)-1-(1-phentyl)-1H-indol-3-yl)-methanone; JWH-210, 
4-ethylnaphthalen-1-yl-(1-pentylindol-3-yl)methanone; JWH-250, 2-(2-methoxyphenyl)-1-(1-pentylindol-3-yl)methanone; PB-22/QUPIC, quinolin-8-yl 1-pentyl-1H-indole-3-
carboxylate; RCS-4, 2-(4-methoxyphenyl)-1-(1-pentyl-indol-3-yl)methanone; THJ-2201, [1-(5-Fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone; UR-144, (1-pentylindol-
3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone; XLR-11, 5F-UR-144[1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; 5F-PB-22, quinolin-8-yl-1-(5-
fluoropentyl)-1H-indole-3-carboxylate.
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drugs detected by blood analysis. In several case reports sedating 
effects and impairment of fine motor skills were noted (120). In 
Poland, a single case showed that use of a synthetic-containing 
product caused effects and impairment similar to THC (121). 
Very few cases of synthetic cannabinoids were detected in the 
blood of drivers in Norway (122, 123).
Health Hazards and Withdrawal
Synthetic cannabinoid use has been associated with serious 
hazardous health effects on multiple systems, and with death 
(124, 125). For example, among 3,572 calls related to synthetic 
cannabinoid use to call centers in the United States, 2,961 had 
a medical outcome, 11.3% callers had a major adverse effect, 
and 15 deaths were reported (126). The most common side 
effects are tachycardia, agitation, irritability, confusion, diz-
ziness, drowsiness, hallucinations, delusions, hypertension, 
nausea, vomiting, vertigo and chest pain (127). Central nerv-
ous system effects range from headache to coma and included 
seizures, myoclonus, catatonic stupor, cerebral ischemia, and 
encephalopathy (128–131). Case reports have documented 
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cardiac complications, ranging from chest pain (132) to myo-
cardial infarction (133, 134), and cardiac arrest (135–137). 
Cases of acute kidney damage and renal failure following 
use of synthetic cannabinoids have also been reported (138). 
Dyspnea, rhabdomyolysis, diaphoresis, and hypokalemia, 
which are not commonly reported by cannabis users, have been 
associated with synthetic cannabinoid use (22). Case reports 
have also described respiratory depression following synthetic 
cannabinoids use (139) and, with chronic use, also pulmo-
nary complications and pneumonia (140, 141). Rare cases of 
cannabinoid-induced hyperemesis syndrome were described 
which included repeated nausea and vomiting, abdominal pain, 
and a compulsion to take hot showers (142, 143).
Prolonged habitual use of synthetic cannabinoids resulted in 
withdrawal syndrome in case reports and in a study of 47 patients 
admitted to detoxification services (144, 145). The symptoms 
were similar to those of withdrawal from THC, including anxiety, 
myalgia, chills, anorexia, mood swings and tachycardia, but were 
more severe and did not seem to improve with the administration 
of THC (144, 146). The differences in presentation may reflect the 
inclusion of extraneous compounds, including amphetamine-like 
stimulants.
Noteworthy, differently from marijuana, while THC is 
metabolized to one active metabolite only, metabolism of new 
synthetic cannabinoids leads to the generation of pharmacologi-
cally active metabolites that remain biologically active and hold 
high affinity for the cannabinoid CB1 receptor (147, 148). As for 
synthetic cathinones, these active metabolites may prolong the 
psychotropic effects of the parent compound thus contributing 
to its toxicity.
ReGULaTiON aND LeGiSLaTiON
Responding to the rapid appearance of NPS with molecular 
structures that have not been covered by legislation, the gov-
ernments of several countries have recognized the need for 
new mechanisms of control with accelerated ways to curtail 
the free sale and distribution of these substances (149). In 
Europe, since 1997 three levels of control were introduced: Early 
Warning System, risk assessments of newly emerged substances 
performed by the European Monitoring Centre for Drugs and 
Drug Addiction (EMCDDA) scientific committee and European 
Council decisions advocating new legislations (132). The posses-
sion, use, and synthesis of synthetic cathinones became subject 
to legal classification in Europe in 2010 (150) and in the United 
States in 2011 (149). Some countries such as Denmark, the UK, 
and Israel (151) opted for “temporary bans” of new psychoactive 
substances considered to pose danger to public health during 
which a risk assessment of a particular compound could be 
performed thus facilitating its subsequent inclusion into the 
Dangerous Drugs Ordinance. Other countries such as New 
Zealand, Ireland, Poland, and Romania (152) chose “pre-market 
approval” regulation regime for synthetic drugs that pose low 
health risk on the base of preclinical and clinical evidence. The 
effectiveness of these legal measures and regulations on the sell-
ing and marketing of the new psychoactive substances has still 
to be assessed.
CONCLUSiON
Synthetic cathinones and synthetic cannabinoids became 
increasingly popular despite the potential harms associated with 
their use. Synthetic cathinones have similar clinical effects to 
amphetamines and MDMA whereas synthetic cannabinoids are 
high-potency, full agonists at cannabinoid receptors and induce 
THC-like effects, but more potent and enduring. Both classes of 
substances have various adverse health effects. Synthetic cathi-
nones cause anxiety, agitation, panic, dysphoria, psychosis, and 
bizarre behavior whereas synthetic cannabinoids cause agitation, 
irritability, confusion, hallucinations, delusions, psychosis, and 
death (as well as other health problems illustrated above in the 
text and in Tables 1 and 2).
Chronic use of synthetic cathinones and synthetic cannabi-
noids results in adverse medical and psychiatric effects that seem 
to be higher than those induced by the natural parent compounds 
(i.e., cathinone and THC). In comparison with other known 
amphetamines, synthetic cathinones such as MEPH and MDPV 
exhibit a pharmacological profile that is more typical of meth-
amphetamine and cocaine, respectively, while methylone shows a 
pharmacological profile that more closely resembles MDMA; yet, 
clinical toxicology of synthetic cathinones is not yet fully charac-
terized. Synthetic cannabinoids show higher toxicity compared 
with natural cannabinoids, and their long-term effects are still to 
be investigated. In view of the increasing demand for these sub-
stances and their severe associated risks, more rigorous research 
on the effects of synthetic cathinones and synthetic cannabinoids 
is urgently required in order to understand their pharmacological 
effects and assist clinicians in managing adverse events.
These two classes of synthetic drugs are composed of phar-
macologically diversified compounds with multiple mechanisms 
of action. Preclinical studies are urgently needed to elucidate 
their single action in both the brain and the periphery as well as 
their synergistic effects and long-term consequences. At clinical 
level, development of combined and integrated pharmacological 
and psychological approaches to treat intoxication symptoms is 
necessary. Treatment protocols currently available for the better-
known parental drugs need to be adapted to face with the increas-
ing number of intoxications reported after the use of synthetic 
cathinones and synthetic cannabinoids.
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